Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.

  title={Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.},
  author={Kuniaki Shirao and Yasuhiro Matsumura and Yasuhide Yamada and Kei Muro and Masahiro Gotoh and Narikazu Boku and Atsushi Ohtsu and Fumio Nagashima and Yasushi Sano and Manabu Mutoh and Yusuke Tanigawara},
  journal={Japanese journal of clinical oncology},
  volume={36 5},
BACKGROUND Oxaliplatin, a platinum compound, has been commonly used around the world for treating advanced colorectal cancer. The generally recommended dose and schedule of oxaliplatin monotherapy is 130 mg/m(2) every 3 weeks. This trial was conducted to evaluate the safety and pharmacokinetics of oxaliplatin monotherapy in Japanese patients with solid tumors. METHODS Oxaliplatin was administered as a 2-h intravenous infusion every 3 weeks at a dose of 90 and 130 mg/m(2). Blood was collected… CONTINUE READING


Publications citing this paper.
Showing 1-9 of 9 extracted citations

The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen

International Journal of Clinical Oncology • 2010
View 2 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 20 references

Clinical pharmacokinetics of oxaliplatin: a critical review.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2000
View 6 Excerpts
Highly Influenced

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2004
View 1 Excerpt

The Japanese edition of the National Cancer InstituteCommon Toxicity Criteria

M. Shimoyama
Jpn J Cancer Chemother • 1999
View 1 Excerpt

Similar Papers

Loading similar papers…